Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?

Abstract

Since the presence of an M-component is an essential disease feature in both multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM), the decrease in the M-protein size applied for response in MM is also a crucial criteria for assessing response in WM. However, WM frequently displays lymphoma-like features that should be included in the response criteria.

• Authors: Joan Bladé, Silvia Montoto, Laura Rosiñol, Emili Montserrat
• Journal: Seminars in oncology (Semin Oncol) Vol. 30 Issue 2 Pg. 329-31 (Apr 2003) ISSN: 0093-7754 [Print] United States
• PMID: 12720163 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2003 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Immunoglobulin M

Topics

• Antineoplastic Agents (therapeutic use)
• Humans
• Immunoglobulin M (blood)
• Multiple Myeloma (blood, drug therapy)
• Prognosis
• Remission Induction
• Treatment Failure
• Treatment Outcome
• Waldenstrom Macroglobulinemia (blood, drug therapy)